JPMorgan Chase & Co’s Cullinan Oncology CGEM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $731K | Buy |
97,069
+53,522
| +123% | +$403K | ﹤0.01% | 3886 |
|
|
2025
Q1 | $330K | Sell |
43,547
-154,667
| -78% | -$1.17M | ﹤0.01% | 4239 |
|
|
2024
Q4 | $2.41M | Buy |
198,214
+169,104
| +581% | +$2.06M | ﹤0.01% | 3272 |
|
|
2024
Q3 | $487K | Buy |
29,110
+5,842
| +25% | +$97.8K | ﹤0.01% | 4029 |
|
|
2024
Q2 | $406K | Buy |
23,268
+3,798
| +20% | +$66.2K | ﹤0.01% | 3951 |
|
|
2024
Q1 | $332K | Sell |
19,470
-5,723
| -23% | -$97.5K | ﹤0.01% | 4190 |
|
|
2023
Q4 | $257K | Buy |
25,193
+879
| +4% | +$8.96K | ﹤0.01% | 4292 |
|
|
2023
Q3 | $220K | Buy |
24,314
+3,635
| +18% | +$32.9K | ﹤0.01% | 4186 |
|
|
2023
Q2 | $223K | Sell |
20,679
-1,564
| -7% | -$16.8K | ﹤0.01% | 4220 |
|
|
2023
Q1 | $228K | Buy |
22,243
+2,858
| +15% | +$29.3K | ﹤0.01% | 4254 |
|
|
2022
Q4 | $205K | Sell |
19,385
-524
| -3% | -$5.54K | ﹤0.01% | 4200 |
|
|
2022
Q3 | $256K | Buy |
19,909
+1,914
| +11% | +$24.6K | ﹤0.01% | 4059 |
|
|
2022
Q2 | $231K | Sell |
17,995
-6,177
| -26% | -$79.3K | ﹤0.01% | 4250 |
|
|
2022
Q1 | $253K | Buy |
24,172
+4,115
| +21% | +$43.1K | ﹤0.01% | 4330 |
|
|
2021
Q4 | $309K | Buy |
20,057
+4,918
| +32% | +$75.8K | ﹤0.01% | 4319 |
|
|
2021
Q3 | $341K | Buy |
15,139
+7,015
| +86% | +$158K | ﹤0.01% | 4148 |
|
|
2021
Q2 | $209K | Sell |
8,124
-30,077
| -79% | -$774K | ﹤0.01% | 4478 |
|
|
2021
Q1 | $1.59M | Buy |
+38,201
| New | +$1.59M | ﹤0.01% | 3373 |
|